Company Theracryf Plc

Equities

EVG

GB00BSVYN304

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Theracryf Plc

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - London S.E. Other stock markets 09:05:18 10/05/2024 pm IST			5-day change	1st Jan Change
0.75 ^GBX	0.00%		0.00%	-53.12%

26/04	Evgen Pharma plc will Change its Ticker to TCF from EVG	CI
26/04	Evgen Pharma plc will Change its Name to TheraCryf plc	CI

Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.

Number of employees: 10

GBP in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	0	nan %	0	100.0 %	-

GBP in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Huw Jones CEO	Chief Executive Officer	62	-
Toni Haenninen DFI	Director of Finance/CFO	-	05/23/05
Glen Clack CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Helen Kuhlman PRN	Corporate Officer/Principal	-	01/21/01

Members of the board	Title	Age	Since
Huw Jones CEO	Chief Executive Officer	62	-
Susan Foden CHM	Chairman	71	21/14/21
Alan Barge BRD	Director/Board Member	-	21/15/21
Toni Haenninen DFI	Director of Finance/CFO	-	05/23/05

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	427,346,895	288,780,685 ( 67.58 %)	0	67.58 %

Name	Equities	%	Valuation
James Robert Kight 12.04 %	33,100,000	12.04 %	365 755 p
Rathbones Investment Management Ltd. 9.382 %	25,789,246	9.382 %	284 971 p
Octopus Investments Ltd. 7.958 %	21,875,000	7.958 %	241 719 p
Vulpes Investment Management Pte Ltd. 7.477 %	20,554,191	7.477 %	227 124 p
First Equity Ltd. 7.276 %	20,000,000	7.276 %	221 000 p
SPARK Venture Management Ltd. 5.888 %	16,186,446	5.888 %	178 860 p
Seneca Partners 5.432 %	14,932,071	5.432 %	164 999 p
AXA Investment Managers UK Ltd. 4.875 %	13,399,724	4.875 %	148 067 p
Chelverton Asset Management Ltd. 4.547 %	12,500,000	4.547 %	138 125 p
RAB Capital Ltd. (Investment Management) 3.183 %	8,750,000	3.183 %	96 688 p

Evgen Pharma Plc

Block 24, Alderley Park Suite 24G13

SK10 4TG, Nether Alderley

+44 1625 315 090

http://www.evgen.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
THERACRYF PLC	-53.12%	4.01M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs